AASOG National Conference 2014 - September 19-20, Ohio
We are pleased to announce the AASOG National Conference 2014
on Sarcoidosis Health Care Disparities and Clinical Research Challenges,
which will be held in Ohio, September 19-20, 2014.
Programme details & Registration
ILD Conference 2014 Presentation and Abstracts online
We are pleased to ainform you that the ILDs Conference presentations as
well as Posters Abstracts have been published at the Conference website:
The 3rd combined WASOG and BAL meeting will be held in Turkey on 8-11
October 2014. On behalf of the WASOG and Turkish Thoracic Society we are
pleased to invite you to the congress. The congress will be held in
Kusadasi which is a resort town near Izmir and ancient Ephesus.
Abstract submission deadline: August 25th!!
For details visit the official congress website at
The FSR Physicians’ Treatment Protocol
FSR (Foundation for Sarcoidosis Research) is committed to addressing
the gaps that exist in sarcoidosis research. This includes the lack
of information and knowledge around the current disease treatment
options. Yet another challenge of “rare disease” is the inherent
rarity of specialists and experts that can help guide treatment
options. While physicians who specialize in sarcoidosis can be
found, many times patients and doctors are challenged by a lack of
information. FSR’s Scientific Advisory Board developed a
Physicians’ Treatment Protocol
that can offer expert information
to physicians to help guide their diagnosis and treatment decisions.
Pulmonary Sarcoidosis: A Guide for the Practicing Clinician
Pulmonary Sarcoidosis: A Guide for the Practicing Clinician is a valuable resource for clinicians of varied disciplines concerning the care of the sarcoidosis patient. Chapters are written by distinguished authors who have extensive experience in caring for these patients.
This guide is fully comprehensive and evidence-based and will be an essential addition to the bookshelves of all whose practice involves the care and treatment of patients with sarcoidosis.
More details & order online
app for iPhone, iPad & Android
This app provides recommendations for the use of methotrexate in
sarcoidosis and everything else you need to know about methotrexate.
The app was developed on behalf of WASOG and is now available for iOS
and Android. Details & Download
Follow WASOG on LinkedIn, Twitter and via our e-Newsletter
In addition to this website WASOG will keep you informed using
several media. Updates include WASOG news, conference updates and other
relevant information we would like to share with you. We therefore
invitite you to subscribe to our e-Newsletter
and/or follow @wasog on Twitter
You may also join our group on
to expand your professional network and participate in discussions.
Sarcoidosis and other ild around the world
To inform you about sarcoidosis and other ild in different countries we ask(ed)
colleagues to summarize the prevalence, the research and important websites, etc. This topic has been added to the WASOG site.
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a
previous clinical tool by Judson MA, et al. A Case Control Etiology
of Sarcoidosis Study (ACCESS) sarcoidosis organ assessment instrument
has been used for more than a decade to establish uniform standards for
the probability of sarcoidosis organ involvement. The ACCESS instrument
has become increasingly outdated as new technologies have been
developed. Furthermore, the ACCESS instrument failed to address all
possible organs involved with sarcoidosis. For these reasons, the World
Association of Sarcoidosis and Other Granulomatous Diseases (WASOG)
developed a new sarcoidosis organ assessment instrument. Various
clinical manifestations were classified as highly probable, at least
probable, possible, or indeterminate when no consensus could be reached.
An instrument was developed by expert opinion that may be useful for the
clinician and researcher in establishing criteria for sarcoidosis organ
Pulmonology meets rheumatology in sarcoidosis: a review on the
therapeutic approach by Drent M. et al. The pathogenesis of
sarcoidosis is not fully elucidated. An exaggerated granulomatous
reaction after exposure to unidentified antigens in genetically
susceptible individuals evokes a clinical situation which we call
sarcoidosis. Between 20 and 70% of patients need systemic therapy. No
firm guidelines exist on whether, when, and how treatment should be
started. Treatment is dependent on the presentation and the
distribution, extensiveness and severity of sarcoidosis. Treatment of
Löfgren's triad-related symptoms starts with NSAIDs; in other more
extensive manifestations of sarcoidosis, the initiating dosage of
glucocorticosteroids is approximately 20 mg daily. In terms of
evidence-based treatment for sarcoidosis, only a few randomized
controlled trials have been done. Identified associations of certain
polymorphisms with severity of the disease and treatment response
suggest future research questions as well as finding the cause(s) of
sarcoidosis, and the elucidation of relevant biomarkers and new
efficient treatments. The increased awareness of long-term side-effects
of glucocorticosteroids and the emergence of new drugs have changed the
treatment of sarcoidosis.
Read more or
View Video Abstract ►
Connective tissue disease related interstitial lung diseases and
idiopathic pulmonary fibrosis: provisional core sets of domains and
instruments for use in clinical trials by Lesley Ann Saketkoo, et
al. Rationale Clinical trial design in interstitial lung diseases (ILDs)
has been hampered by lack of consensus on appropriate outcome measures
for reliably assessing treatment response. In the setting of connective
tissue diseases (CTDs), some measures of ILD disease activity
and severity may be confounded by non-pulmonary comorbidities.
Identification of consensus preliminary domains and instruments to
measure them was attained and is a major advance anticipated to
facilitate multicentre RCTs in the field.
Read full paper
An official American Thoracic Society/European Respiratory Society
Statement: update of the international multidisciplinary classification
of the idiopathic interstitial pneumonias by Travis WD et al by
Travis WD et al. In 2002 the American Thoracic Society/European
Respiratory Society (ATS/ERS) classification of idiopathic interstitial
pneumonias (IIPs) defined seven specific entities, and provided
standardized terminology and diagnostic criteria. In addition, the
historical "gold standard" of histologic diagnosis was replaced by a
multidisciplinary approach. The objective of this statement is to update
the 2002 ATS/ERS classification of IIPs. The clinical course of
idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia is
recognized to be heterogeneous. Acute exacerbation of IIPs is now well
defined. A substantial percentage of patients with IIP are difficult to
classify, often due to mixed patterns of lung injury. A classification
based on observed disease behavior is proposed for patients who are
difficult to classify or for entities with heterogeneity in clinical
course. This update is a supplement to the previous 2002 IIP
classification document. It outlines advances in the past decade and
potential areas for future investigation.
Find all our selected literure, inluding archived pubmed selections, on our
key papers page!